Chen L Y, Ballew J D, Herron K J, Rodeheffer R J, Olson T M
Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Clin Pharmacol Ther. 2007 Jan;81(1):35-41. doi: 10.1038/sj.clpt.6100016.
The cardiac sodium channel (SCN5A) is a target for the treatment of arrhythmias. We hypothesized that vulnerability to atrial fibrillation (AF) could be caused by genetic variation in SCN5A. We recruited 157 patients with early-onset AF who lacked traditional risk factors, and 314 matched controls. SCN5A was subject to targeted genotyping of a common loss-of-function H558R polymorphism and comprehensive mutation scanning. Genotype frequencies in the AF cohort vs controls were as follows: HH, 50 vs 63%; HR, 40 vs 33%; and RR, 10 vs 4% (P=0.008). Additional coding sequence mutations were ruled out. The R558 allele was more common in patients than in controls (30 vs 21%, P=0.002), conferring an odds ratios for AF of 1.6 (95% confidence interval 1.2-2.2). The SCN5A R558 allele, present in one-third of the population, thus constitutes a risk factor for lone AF and may increase susceptibility to sodium channel blocker-induced proarrhythmia.
心脏钠通道(SCN5A)是心律失常治疗的一个靶点。我们推测心房颤动(AF)的易感性可能由SCN5A的基因变异引起。我们招募了157例无传统危险因素的早发性AF患者以及314例匹配的对照。对SCN5A进行常见功能缺失性H558R多态性的靶向基因分型和全面的突变扫描。AF队列与对照组的基因型频率如下:HH型,分别为50%和63%;HR型,分别为40%和33%;RR型,分别为10%和4%(P=0.008)。排除了其他编码序列突变。R558等位基因在患者中比在对照中更常见(分别为30%和21%,P=0.002),AF的优势比为1.6(95%置信区间1.2 - 2.2)。SCN5A的R558等位基因存在于三分之一的人群中,因此构成孤立性AF的一个危险因素,并且可能增加对钠通道阻滞剂诱导的心律失常的易感性。